One study found that within the same institution, RCC patients with a BMI ≥ 25 kg/m2 (subjects with overweight or obesity) treated with CPI had a trending reduction in overall survival, whereas patients treated with therapies targeting VEGF or mTOR had improved survival [19]. Here, MTOR is linked to renal cell carcinoma.